Mr. Erck was named president and chief executive officer of Novavax in April 2011. He became a Novavax director in June 2009 and served as its executive chairman of the board beginning in February 2010. From 2000 to 2008, Mr. Erck was president and chief executive officer of IOMAI Corporation, leading the company through an initial public offering and a merger with Intercell, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate. Mr. Erck previously served as president and chief executive officer at Procept, a publicly traded immunology company, as vice president of corporate development at Integrated Genetics (now Genzyme), and in management positions within Baxter International. Mr. Erck currently sits on the board of directors of MaxCyte, Inc. and the MdBio Foundation. He received an undergraduate degree from the University of Illinois and a master’s degree in business administration from the University of Chicago Booth School of Business.
Stanley C. Erck
President and Chief Executive Officer
View more >>
Dr. Glenn is the president of research and development and leads the discovery, clinical, and regulatory teams. He has spent 28 years in the design and development of vaccines, vaccine delivery, and adjuvants. He has led the development of products from concept to late-stage clinical development, including COVID-19, RSV, recombinant adjuvanted seasonal and pandemic influenza vaccines, Ebola, and an Enterotoxigenic E. coli vaccine patch, and participated in other programs including the development of a malaria vaccine. He is the cofounder of IOMAI and provided the scientific and technical leadership that led to the acquisition by Intercell in 2008. He worked for Intercell from 2008 to 2010. He is the coauthor of more than 100 peer-reviewed scientific publications. Dr. Glenn was board certified and practiced pediatrics prior to completing a Medical Research Fellowship at the Walter Reed Army Institute of Research where he continued as a clinician-researcher prior to entering into commercial vaccine development in 1997. Dr. Glenn received a bachelor of arts degree in biology and chemistry from Whitman College in Washington and a doctor of medicine degree from Oral Roberts University School of Medicine in Oklahoma.
Gregory Glenn, M.D.
President. Research and Development
View more >>
Mr. Trizzino is executive vice president, chief business officer, and chief commercial officer with responsibility for all pre-commercial and commercial launch strategy and execution, financial reporting, corporate funding, and investor/public relations. He previously served as senior vice president of commercial operations beginning in 2014. Mr. Trizzino originally joined Novavax in 2009 with a broad range of experiences in small-to-large, publicly held companies. He has an extensive background in the vaccine market with previous roles overseeing commercialization, vaccine policy, strategic development, business development, financing, investor relations, and public relations. In 2011, Mr. Trizzino joined Immunovaccine as its CEO and successfully led the company into clinical development of its lead candidate while securing the required funding commitments in the equity market as well as non-dilutive sources. Prior to his tenures at Novavax and Immunovaccine, Mr. Trizzino had leadership responsibilities at MedImmune, LLC (an AstraZeneca company), ID Biomedical, and Henry Schein, Inc., which were all companies focused on infectious disease vaccine markets. Mr. Trizzino received a bachelor of science degree from Long Island University, CW Post and a master of business administration degree from New York University, Stern School of Business.
John J. Trizzino
Executive Vice President, Chief Commercial Officer and Chief Business Officer
View more >>